The evolving role of nuclear medicine and particularly of PET/CT over time in prostate cancer is represented by expansion of applications of already used radiopharmaceuticals in everyday clinical practice, by newly utilized radiopharmaceuticals, as well as by the introduction of new imaging modalities such as PET/MRI.
